| FDA advisory panel will convene to reconsider approval of fenofibrate |
|
| Medical News Today: Abbot's blockbuster cholesterol drug, Trilipix (fenofibrate), which is taken in combination with a statin was found to be no better at reducing heart attack risk than taking the statin alone, in a trial involving diabetic patients. An FDA Advisory Committee will meet this week to decide whether the FDA should alter the drug's key indication. |